Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 18Triple Negative Breast Neoplasms 16Carcinoma, Transitional Cell 4Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Salivary Gland Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Urothelial Cancer 1Meningeal Carcinomatosis 1Lung Diseases 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Etoposide 27Carboplatin 26atezolizumab 16durvalumab 12Cisplatin 10Topotecan 9Drug Therapy 9PM 01183 7pembrolizumab 5Radiotherapy 5Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Irinotecan 4Injections 4Immunotherapy 4trilaciclib 3toripalimab 3Temozolomide 3Radiosurgery 3Bevacizumab 3AMG 757 3tislelizumab 2monalizumab 2irinotecan sucrosofate 2enzalutamide 2apatinib 2Platinum 2Nivolumab 2Itraconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Small Cell Lung Carcinoma × sacituzumab govitecan × Clear all
NCT07339059 2026-04-23

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Henry Ford Health System

Phase 2 Recruiting
35 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡